Merck & Co., Inc. (MRK) News Today

Merck & Co., Inc. (NYSE: MRK) is under pressure despite a strong quarterly earnings beat. Investors appear more focused on the company’s longer-term transition away from Keytruda than on the latest results.

• Positive Sentiment: Merck reported quarterly adjusted earnings of $2.49 per share, well above the $2.09 analyst consensus, while revenue of $18.09 billion exceeded the $17.33 billion estimate. The company also raised its adjusted profit outlook. Merck earnings press release
• Positive Sentiment: Keytruda sales were stronger than expected, including growth from the newer injectable Qlex formulation. Winrevair also contributed to revenue growth, supporting Merck’s effort to diversify its pharmaceutical portfolio. CNBC Merck earnings report
• Positive Sentiment: Keytruda reduced the risk of disease progression by 43% in a Phase 3 endometrial-cancer trial, adding support for expanding the drug’s indications. Recent oncology data and the Moderna partnership’s melanoma-vaccine results also reinforce Merck’s pipeline potential. Keytruda endometrial cancer trial
• Positive Sentiment: Wells Fargo maintained a Buy view, while other analyst commentary has pointed to potential appreciation as Merck’s newer medicines and oncology pipeline mature. Wells Fargo Merck rating

• Neutral Sentiment: Reported profit declined year over year to $5.07 billion, or $2.04 per share, from $5.79 billion, or $2.32 per share, despite the adjusted earnings beat. Wall Street Journal Merck revenue report

• Negative Sentiment: Wall Street is looking beyond the quarterly beat because Keytruda, Merck’s largest revenue driver, faces a looming patent cliff. Investors want clearer evidence that Qlex, Winrevair and pipeline assets can offset eventual Keytruda erosion. Barron’s Merck earnings analysis
• Negative Sentiment: Earlier outlook concerns included weakening Gardasil demand, declining estimates and difficult comparisons. The Moderna-Merck melanoma-vaccine results were positive clinically but reportedly below investor hopes, limiting their immediate stock-market impact. Merck and Moderna cancer vaccine results